CD5 and T-cell immunodeficiency: Although complete T-cell aplasia was not observed in clinical trials of CD5 or CD7 CAR-T therapy, the risk of severe T-cell immunodeficiency resulting from simultaneous targeting of two T-cell-pan markers remains a major concern.